More than half the gross proceeds of Chimerix Inc.'s $103.8 million from a public offering will go toward advancing the oral nucleotide analogue lipid-conjugate drug brincidofovir, the company said in its 424B5 filing with the SEC, pricing 7.3 million shares at $14.22 each in a deal set to close next week. Read More
Launched last year with a portfolio of early stage small molecules and late-stage clinical assets assembled through a pair of acquisitions, Voltarra Pharmaceuticals Inc. has moved like lightning – a strategy underpinning the company's name – into phase III trials for its lead candidate. Read More
Lysogene SAS raised €16.5 million (US$22.6 million) in a series A round to continue its clinical development of SAF-301, a gene therapy treatment for Sanfilippo syndrome type A, a rare neurodegenerative disorder arising from impaired breakdown of the cell surface and extracellular matrix component heparan sulfate. Read More
Sending a clear signal to Washington, Louisiana is poised to become the second state to enact a law recognizing the right of terminally ill patients, who have run out of options, to try investigational drugs and devices. Read More
Cour Pharmaceutical Development Co. Inc., a small company developing nanotechnology-based immunotherapies for acute inflammation and autoimmune disease, has appointed Pfizer R&D veteran Catherine Mackey as chairman of its board. Read More
Inhibikase Therapeutics Inc., of Atlanta, said it received FDA orphan drug designation for imatinib to treat progressive multifocal leukoencephalopathy (PML), a rare side effect of small-molecule and antibody drugs given to patients with autoimmune diseases such as arthritis and multiple sclerosis and a disease that occurs in 1 percent to 3 percent of clinical AIDS patients. Read More
Amgen, of Thousand Oaks, Calif., said The New England Journal of Medicine published results from a phase I study suggesting that inhibiting thymic stromal lymphopoietin (TSLP) could benefit the treatment of asthma. Read More
Daiichi Sankyo Co. Ltd., of Tokyo, began a three-year research project with Sanford-Burnham Medical Research Institute, of La Jolla, Calif., to investigate cardiovascular-metabolic diseases. Read More
Boehringer Ingelheim GmbH, of Boehringer, Germany, presented results from the phase III VIVACITO study at the American Thoracic Society meeting in San Diego, showing that the fixed-dose combination of tiotropium and olodaterol, delivered via the Respimat inhaler, demonstrated a statistically significant improvement over both monotherapy treatment (p < 0.0001) and placebo (p < 0.0001) in the primary endpoint, defined as the forced expiratory volume in one second. Read More
